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Abstract 
Dysregulation of microRNAs has been implicated in many cardiovascular diseases including fibrosis. 
Here we report that miR-433 was consistently elevated in three models of heart disease with 
prominent cardiac fibrosis, and was enriched in fibroblasts compared to cardiomyocytes. Forced 
expression of miR-433 in neonatal rat cardiac fibroblasts increased proliferation and their differentiation 
into myofibroblasts as determined by EdU incorporation, α-SMA staining, and expression levels of 
fibrosis-associated genes. Conversely, inhibition of miR-433 exhibited opposite results. AZIN1 and 
JNK1 were identified as two target genes of miR-433. Decreased level of AZIN1 activated TGF-β1 while 
down-regulation of JNK1 resulted in activation of ERK and p38 kinase leading to Smad3 activation and 
ultimately cardiac fibrosis. Importantly, systemic neutralization of miR-433 or adeno-associated virus 9 
(AAV9)-mediated cardiac transfer of a miR-433 sponge attenuated cardiac fibrosis and ventricular 
dysfunction following myocardial infarction. Thus, our work suggests that miR-433 is a potential target 
for amelioration of cardiac fibrosis. 
Key words: cardiac fibrosis, miR-433, AZIN1, JNK1. 
Introduction 
Cardiac fibrosis, a hallmark of most 
cardiomyopathies, is characterized by excessive 
extracellular matrix accumulation contributing to the 
destruction of normal tissue architecture and 
progressive organ dysfunction [1, 2]. Cardiac fibrosis 
is a strong driver of adverse ventricular remodeling 
and heart failure that occurs after a variety of different 
cardiac injuries, such as myocardial infarction (MI) 
and hemodynamic stress as seen in hypertrophic and 
dilated cardiomyopathies [3, 4]. Although acetyl 
choline esterase (ACE) inhibition, angiotensin II 
receptor antagonists, and recently LCZ696 (an 
angiotensin II type 1 receptor-neprilysin inhibitor) can 
partially reverse remodeling, no effective anti-fibrotic 
therapeutic strategies are currently available [1, 5, 6]. 
The lack of an effective therapy for cardiac fibrosis 
and cardiac remodeling is in part responsible for the 
morbidity, mortality, and healthcare expenditure 
attributable to heart failure [2, 5]. Therefore, novel 
anti-fibrotic strategies represent a critical unmet 
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clinical need [2, 5].  
MicroRNAs (miRNAs, miRs) are small 
noncoding RNAs, which repress gene expression by 
degradation or translational inhibition of target 
mRNAs [7]. A single mRNA can be regulated by 
multiple miRNAs, while individual miRNAs are 
capable of regulating tens to hundreds of distinct 
target genes [7, 8]. As approximately 60% of 
protein-coding genes are regulated by miRNAs, they 
have emerged as powerful regulators for almost all 
essential biological processes including cellular 
proliferation, differentiation, apoptosis, development, 
and metabolism [9, 10]. Emerging data have 
suggested that aberrant expression of miRNAs could 
lead to a profound disturbance of target gene network 
and signaling cascades that participate in many 
pathological phenotypes. One such example is of 
adverse cardiac remodeling and fibrosis [1, 11, 12]. 
Increased pro-fibrotic miRNAs such as miR-21, 22, 
and 34a and decreased anti-fibrotic miRNAs such as 
miR-24, 15 family, 26a, and 29b have been reported to 
contribute to cardiac fibrosis [13-20]. These 
observations indicate that manipulation of miRNAs 
may serve as a novel potential therapeutic approach 
to combat cardiac fibrosis. An unexplored candidate 
located on chromosome 12, miR-433, has been 
reported to be up-regulated in renal fibrosis and liver 
fibrosis [21, 22]. However, the role of miR-433 in the 
heart and especially in cardiac fibrosis is unclear.  
In the present study, based on miRNA arrays, 
we noted that miR-433 was significantly increased in 
ventricle samples at 21-days following MI in mice. We 
further validated up-regulation of miR-433 in a rodent 
model of doxorubicin-induced cardiomyopathy and 
human dilated cardiomyopathy (DCM). Also, 
over-expression of miR-433 increased the 
proliferation of cardiac fibroblasts and promoted their 
differentiation into myofibroblasts, whereas 
knockdown of miR-433 suppressed these responses 
upon transforming growth factor-β (TGF-β) or 
Angiotensin II (Ang II) stimulation. Our work further 
identified AZIN1 and JNK1 as two target genes of 
miR-433. Importantly, treatment with miR-433 
antagomir or adeno-associated virus 9 
(AAV9)-mediated cardiac transfer of a miR-433 
sponge improved post-MI cardiac function and 
attenuated cardiac fibrosis in adult mice. Collectively, 
our findings indicate that miR-433 promotes cardiac 
fibrosis and therefore inhibition of miR-433 might be 
useful for the treatment of cardiac fibrosis.  
Materials and Methods 
Ethics Statement 
All animals were raised at the Experimental 
Animal Center of Nanjing Medical University 
(Nanjing, China) or Shanghai University (Shanghai, 
China). All procedures with animals were in 
accordance with the guidelines on the use and care of 
laboratory animals for biomedical research published 
by National Institutes of Health (No. 85-23, revised 
1996). The experimental protocol was reviewed and 
approved by the ethical committees of Nanjing 
Medical University and Shanghai University. All 
human investigations conformed to the principles 
outlined in the Declaration of Helsinki and was 
approved by the institutional review committees of 
Nanjing Medical University. All participants gave 
written informed consent before enrollment in the 
study. Human left ventricular tissue samples were 
obtained from 4 patients with dilated 
cardiomyopathy (DCM) undergoing cardiac 
transplantation and 4 healthy donors (The First 
Affiliated Hospital of Nanjing Medical University). 
Isolation of Cardiac Fibroblasts, Culture, and 
Transfection 
Cardiac fibroblasts were isolated from 1 to 
3-day-old SD rats. Ventricles were finely minced and 
digested in trypsin buffer (60% trypsin and 40% 
collagenase). Cell suspensions were centrifuged, 
resuspended in DMEM (Gibco, Grand Island, CA, 
USA) with 10% fetal bovine serum (FBS), 100 U/ml 
penicillin and 100 μg/ml streptomycin, and plated for 
2 h under standard culture conditions (37°C in 5% 
CO2 and 95% O2) which allowed fibroblast attachment 
to the culture plates.  
All transfections and assays on cardiac 
fibroblasts were conducted in low serum medium (1% 
FBS). Cardiac fibroblasts at passage 2 were exposed to 
either miRNA agomir versus negative control (100 
nM), or antagomir versus negative control (200 nM) 
(RiboBio, Guangzhou, China) for 48 h, and treated 
with 10 ng/ml recombinant human TGF-β1 for 24 h 
(Peprotech, Rocky Hill, NJ, USA) or 100 nM Ang II for 
48 h (Sigma, St. Louis, MO, USA), respectively. 
siRNAs for AZIN1, JNK1, and negative controls were 
purchased from Invitrogen Carlsbad, CA. Plasmids 
over-expressing AZIN1 or JNK1 were purchased from 
Sangon Biotech, Shanghai, China. Transfections with 
siRNAs (50 nM) or plasmids (50 nM) for 48 h were 
carried out using Lipofectamine RNAiMAX 
Transfection Reagent (Invitrogen). p38 MAP kinase 
inhibitor SB202190 (Sigma, 10 μM, 1 h), ERK inhibitor 
U0126 (Sigma, 10 μM, 1 h), and Smad3 inhibitor SIS3 
(Millipore, 1 μM, 48 h) were used to treat cells in the 
presence or absence of miR-433 agomir. 
Animal Models 
Eight-week-old male C57BL/6 mice were used 
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in this study. MI was generated by ligating the left 
anterior descending coronary artery (LAD) using a 
7/0 silk thread while sham was created by the same 
process but without LAD ligation. 
Doxorubicin-induced cardiomyopathy mouse model 
was induced by chronically treating mice with either 
doxorubicin or phosphate-buffered saline (PBS) by 
four intraperitoneal (i.p) injections (day 0, 2, 4 and 6) 
at a dose of 4 mg/kg. All mice were sacrificed after 4 
weeks.  
To determine if inhibition of miR-433 is sufficient 
to prevent cardiac fibrosis in vivo, mice were injected 
via tail vein with 80 mg/kg antagomir (a 2’OME+ 
5’chol modified miR-433 inhibitor) or the scramble 
control (Ribobio, Guangzhou, China) for 3 
consecutive days and subjected to LAD ligation. AAV 
represents an efficient and safe vector for in vivo gene 
transfer and serotype 9 is significantly cardiotropic 
[23-26]. Thus, besides miR-433 antagomir, the 
cardiotropic miR-433 sponge AAV9 was used to 
determine further if cardiac inhibition of miR-433 is 
sufficient to prevent fibrosis in vivo. In brief, mice 
were randomly chosen to receive a single-bolus tail 
vein injection of either miR-433 sponge AAV9 or 
miR-scramble (Hanheng Biotechnology, Shanghai, 
China) at 1*1011 vg (viral genomes) per animal. After 1 
week, mice were subjected to LAD ligation and finally 
sacrificed at 3 weeks post-MI.  
miRNA Array and Gene-Chip Analysis 
Total RNA extracted from ventricular tissues 21 
days post-MI or sham control was used for miRNA 
arrays based on Affymetrix 4.0 (OE Biotech’s, 
Shanghai, China). Additionally, total RNA extracted 
from ventricular tissues 21 days post-MI injected with 
miR-433 antagomir or scramble control was used for 
gene-chip analysis based on Agilent SurePrint G3 
Mouse GE (8*60K, Design ID: 028005) Microarray (OE 
Biotech’s, Shanghai, China). The MIAME compliant 
data have been submitted to Gene Expression 
Omnibus (GEO, platform ID: GSE74135 for miRNA 
array and GSE74206 for gene-chip analysis, 
respectively). 
Quantitative Real-time Polymerase Chain 
Reactions (qRT-PCRs) 
Total RNAs were extracted from cardiac 
fibroblasts and heart samples by using miRNeasy 
Mini Kit (Qiagen, Hilden, Germany) according to 
manufacturer’s instructions. Total RNAs (400 ng) 
were reverse transcribed using Bio-Rad iScriptTM 
cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA) to 
obtain cDNAs. The expression levels of TGF-β, 
α-SMA, Col1a1, and Col3a1 were analyzed by using 
Bio-Rad SYBR qPCR (Bio-Rad, Hercules, CA, USA) on 
ABI-7900 Real-Time PCR Detection System (7900HT, 
Applied Biosystems, CA, USA). 18S RNA was used as 
an internal control for gene expressions. Primer 
sequences used in the study are listed in 
Supplemental Table 1. For quantitative miRNA 
analysis, the Bulge-LoopTM miRNA qPCR Primer Set 
(RiboBio) was used to determine the expression levels 
of miRNAs with Takara SYBR Premix Ex TaqTM (Tli 
RNaseH Plus) on ABI-7900 Real-Time PCR Detection 
System (Applied Biosystems). U6 was used as an 
internal control for miRNA template normalization. 
Pharmacokinetics of miRNA 
miR-433 antagomir or the scramble control 
(Ribobio, Guangzhou, China) was prepared in PBS 
and administered via tail vein at a dose of 7.5 mg/kg 
for each mice. Subsequently, mice were sacrificed and 
plasma and heart tissues were collected immediately 
at different time points of 5, 10, 15, 30, 60, 120, 240, 
480, 1320 and 1440 minutes after injection (n=5 per 
group for each time point) [27]. miR-433 expression 
levels in plasma and heart samples were determined 
using qRT-PCRs as described above. 
Immunofluorescence and EdU Staining 
Cardiac fibroblasts were fixed in 4% 
paraformaldehyde (PFA) for 20 min at room 
temperature. Cells were then permeabilized with 0.2% 
Triton X-100 for 20 min and blocked with 10% goat 
serum in PBS-Tween for 1 h at room temperature. 
Subsequently, cardiac fibroblasts were incubated with 
α-SMA-Cy3 antibody (1:500, Sigma, St. Louis, MO, 
USA) diluted in 10% goat serum overnight at 4°C. To 
detect proliferation, EdU assays were performed 
using Click-iT Plus EdU Alexa Fluor 488 Imaging Kit 
(Invitrogen) according to manufacturer’s instructions. 
Cell nuclei were counterstained with DAPI and the 
number of EdU-positive nuclei was calculated. Fifteen 
fields/sample (200 x magnification) were viewed 
under a confocal microscope (Carl Zeiss, Thuringia, 
Germany). 
Sections of heart samples were cut at a thickness 
of 5-6 μm. Subsequently, the sections were fixed in 4% 
PFA for 20 min at room temperature, permeabilized 
with 0.2% Triton X-100 for 20 min, and then blocked 
with 10% goat serum in PBS-Tween for 1 h at room 
temperature. Next, the sections were incubated with 
diluted primary antibodies at 4°C overnight; the 
following antibodies were used: α-SMA-Cy3 antibody 
(1:500, Sigma), Vimentin antibody (1:100, Abcam), 
Ki67 antibody (1:100, Abcam), and pHH3 antibody 
(1:100, Abcam). After three washes with PBS for 5 min 
each, the sections were incubated with secondary 
antibodies or other dyes at room temperature for 2 h. 
Fifteen fields/sample (400x magnification) were 
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viewed under a confocal microscope (Carl Zeiss).  
Western Blotting Analysis 
Cardiac fibroblasts and heart samples were lysed 
using RIPA buffer (Beyotime Institute of 
Biotechnology, Nantong, China), which contained a 
protease inhibitor cocktail (Sigma). The concentration 
of protein samples was evaluated by Bicinchoninic 
Acid Protein Assay Kit (Thermo Fisher, Waltham, 
MA, USA). Equal amounts of protein were separated 
in SDS-PAGE and blotted onto PVDF membranes. 
The primary antibodies used were from the following 
sources: α-SMA (1:1000, Sigma), TGF-β (1:1000, Cell 
Signaling Technology, Boston, MA, USA), p38 (1:1000, 
CST), p-p38 (1:1000, CST), ERK (1:1000, CST), p-ERK 
(1:1000, CST), p-Smad3 (1:1000, CST), Smad3 (1:1000, 
CST), JNK1 (1:1000, CST), AZIN1 (1:500, Proteintech, 
Wuhan, China), CTGF (1:500, Proteintech, Wuhan, 
China), Col1a1 (1:500, Proteintech), Col3a1 (1:500, 
Proteintech), MMP2 (1:500, Proteintech), MMP9 
(1:500, Proteintech) and GAPDH (1:10000, Kangchen, 
Shanghai, China). All proteins were visualized by 
ECL Chemiluminescence Kit (Thermo Fisher) and the 
quantification of each band was performed using 
Imagelab Software (Bio-Rad) with GAPDH as a 
loading control. 
Luciferase Reporter Assay 
A fragment of the 3’UTRs of AZIN1 or JNK1 
containing the target site of miR-433 was obtained by 
PCR amplification and then cloned into the 
pGL3-Basic Vector (Promega, Madison, WI, USA) to 
generate the AZIN1 or JNK1 wt-luc vector. The 
AZIN1 or JNK1 mutant-luc vector was generated by 
using the MutaBest kit (Takara, Tokyo, Japan). 
Forty-eight hours after transfection, luciferase 
activities were measured using a dual luciferase 
reporter assay system (Promega) following a standard 
procedure.  
Echocardiography 
Three weeks after the injection of miR-433 
antagomir, mice were anesthetized with 1.5–2% 
isoflurane and then evaluated by Vevo 2100 
echocardiography (VisualSonics Inc, Toronto, 
Ontario, Canada) with a 30 MHz central frequency 
scan head to detect cardiac function. The following 
parameters were measured from M-mode images 
taken from the parasternal short-axis view at 
papillary muscle level: left ventricular fractional 
shortening (FS) and left ventricular ejection fraction 
(EF). The left ventricle internal diameter (LVID), 
interventricular septum (IVS), and left ventricle 
posterior wall (LVPW) in diastole or systole were also 
measured. At least three measurements were obtained 
and averaged for each mouse. 
TTC staining 
At 3 days’ post LAD ligation, mice were 
anesthetized with intraperitoneal injection of 0.5 
mg/g tribromoethanol. Subsequently, 1 ml Evans 
blue (BioSharp, Anhui, China) was slowly injected 
into inferior vena and the heart was removed 
immediately. After storage for 15 minutes at -20°C, 
the heart was cut into 5 transverse slices at 1 mm 
thickness across the long axis. The slices were then 
stained with 1% triphenyltetrazolium chloride (TTC, 
Amresco, OHIO, USA) in PBS for 10 min at 37°C 
following which the slices were fixed with 4% PFA 
and analyzed. The final infarct size was calculated by 
Image J Software (National Institutes of Health). 
Masson’s Trichrome Staining 
Heart samples were fixed in 4% PFA and then 
embedded in paraffin. Five μm-thick sections were 
subjected to Masson’s trichrome staining following a 
standard procedure. Images of the left ventricular 
area of each section were taken by Nikon model (200x 
magnification) with Spot Insight camera. Image J 
Software (National Institutes of Health) was used to 
quantify fibrotic region in each section. The 
percentage of fibrosis was measured as fibrosis 
areas/total left ventricular areas x 100%. 
Collagen content assay 
A quantitative dye-binding method was used to 
determine the collagen content. Analysis of heart 
tissues was performed using Sircol assay (Biocolor, 
Carrickfergus, UK) according to manufacturer's 
instructions. In this assay, each heart sample was 
weighed and homogenized with pepsin. The BioTek 
Software (Hercules, CA, USA) was used to quantify 
collagen content in each sample. 
Statistical Analysis 
Data were presented as mean ± SE. A Student’s 
t-test, Chi-squares test or one-way ANOVA followed 
by Bonferroni’s post-hoc test was used to compare the 
one-way layout data when appropriate. P values less 
than 0.05 were considered to be statistically different. 
All analyses were performed using GraphPad Prism 
5. 
Results 
miR-433 is Increased in Cardiac Fibrosis 
miRNA arrays were used to determine aberrant 
expressions of miRNAs, which might contribute to 
cardiac fibrosis in the post-MI ventricle at a time point 
notable for prominent fibrosis. A total of 26 miRNAs 
were found to be dysregulated (Fold change >2.0; 
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P<0.05; Figure 1A and Supplemental Table 2). 
Interestingly, the top 3 dysregulated miRNAs 
including miR-34b-3p, 34c-5p, and 34c-3p belong to 
the miR-34 family, whose inhibition has been shown 
to attenuate pathological cardiac remodeling [13]. 
Since miR-433 (number fourth) has previously been 
reported to participate in kidney and liver fibrosis [21, 
22] but has not so far been explored in the 
myocardium and during cardiac fibrosis, we explored 
its function further.  
Based on the qRT-PCR analysis, we confirmed 
that miR-433 was upregulated in heart samples with 
fibrosis from mice 3 weeks post-MI (Figure 1B). To 
exclude the possibility that increased miR-433 is 
specific to cardiac fibrosis post-MI, we also 
determined its expression in doxorubicin-induced 
cardiomyopathy rodent model and in human dilated 
cardiomyopathy (DCM) (Figure 1B). The clinical 
information and echocardiography parameters for 
DCM patients are presented in Supplemental Table 3. 
The DCM sample size is small due to the difficulty of 
acquiring human heart tissues. Interestingly, miR-433 
was consistently upregulated in all three models, i.e., 
in heart tissues with fibrosis, in doxorubicin-induced 
cardiomyopathy, and in patients with DCM (Figure 
1B). Thus, there appeared to be a strong correlation 
between the presence of cardiac fibrosis and an 
increase in miR-433 expression in several different 
cardiac diseases. Furthermore, miR-433 was also 
increased in cultured neonatal rat cardiac fibrosis 
models stimulated by TGF-β or Ang II (Figure 1C-D). 
Taken together, these data supported a potential role 
for miR-433 in cardiac fibrosis. 
 
 
Figure 1: miR-433 is increased in cardiac fibrosis. A, dysregulated miRNAs in hearts from 21 days post-myocardial infarction (MI) versus sham control mice 
(n=4); B, upregulated miR-433 in ventricle samples from 21 days post-MI mice (n=4), a rodent model of doxorubicin (Dox)-induced cardiomyopathy (n=6), and 
human dilated cardiomyopathy (n=4); C-D, increased miR-433 in two in vitro cardiac fibrosis model induced either by TGF-β or Angiotensin II (n=6); E, expression 
of miR-433 in neonatal cardiac fibroblasts (NRCF) compared to cardiomyocytes (NRCM) (n=6); F, markers for pathological hypertrophy (ANP, BNP and Myh7) and 
extracellular matrix proteins (CTGF, TSP-1, Col1a1 and Col3a1) in cardiomyocytes with miR-433 overexpression (n=6). Scale bar: 50 μm. *, P<0.05, **, P<0.01, ***, 
P<0.001 versus respective controls. 
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Figure 2: Antagonizing miR-433 attenuates cardiac fibrosis and preserves ventricular function post-myocardial infarction. A, decreased miR-433 
in hearts from mice treated with miR-433 antagomir (n=6); B, preserved left ventricular fractional shortening (FS) and ejection fraction (EF); C, reduced cardiac 
fibrosis; D, decreased collagen content in myocardial infarction (MI) with miR-433 inhibition, as evidenced by echocardiography (n=6), Masson’s trichrome staining 
(n=4), and Sircol assay (n=4); E, no difference in the infarct size between mice treated with miR-433 antagomir or negative control 3 days post-MI (n=7). Scale bar: 
100 μm. *, P<0.05, **, P<0.01, ***, P<0.001 versus respective controls. 
 
In vivo Inhibition of miR-433 Preserves Cardiac 
Function and Prevents Fibrosis  
Next, we determined the relative expression 
level of miR-433 in isolated neonatal rat cardiac 
fibroblasts versus cardiomyocytes, and demonstrated 
higher expression level in fibroblasts compared to 
cardiomyocytes (Figure 1E). Forced expression of 
miR-433 in cardiomyocytes did not lead to an 
elevation of markers for pathological hypertrophy 
(ANP, BNP, and Myh7) or extracellular matrix 
proteins (CTGF, TSP-1, Col1a1 and Col3a1) (Figure 
1F) supporting a more prominent role for miR-433 in 
fibroblasts rather than cardiomyocytes. 
To evaluate the effect of miR-433 inhibition on 
cardiac fibrosis, we administrated miR-433 antagomir 
in mice via tail vein to downregulate miR-433 in vivo. 
First, the pharmacokinetic analysis for miR-433 
antagomir was performed by measuring miR-433 
expression level in both plasma and heart samples at 
different time points after mice were administrated 
with a single bolus of miR-433 antagomir at the dose 
of 7.5 mg/kg as previously reported [27]. The 
pharmacokinetic analysis showed that miR-433 was 
significantly downregulated in plasma and heart 
samples at 10 min post injection maintaining the low 
expression level thereafter (Supplemental Figure 1). 
Next, to explore whether antagonizing miR-433 
attenuates cardiac fibrosis and preserves ventricular 
function post-MI, we treated mice with miR-433 
antagomir or scrambled negative control via tail vein 
injection for 3 consecutive days and subjected them to 
MI or sham surgery. Then mice were sacrificed 3 
weeks after MI and the loss of miR-433 in the heart 
was confirmed by qRT-PCRs (Figure 2A). 
Echocardiography showed that miR-433 antagomir 
preserved cardiac function including FS and EF 
(Figure 2B), and also reversed MI-induced increase in 
systolic left ventricle internal diameter (LVID;s) and 
diastolic left ventricle internal diameter (LVID;d) as 
shown in Supplemental Table 4. Importantly, 
inhibition of miR-433 also attenuated cardiac fibrosis 
as evidenced by reduced collagen deposition and 
content in MI heart tissues (Figure 2C-D). In 
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particular, we evaluated the effect of miR-433 
inhibition on cardiac infarction 3 days after MI; the 
purpose was to determine whether miR-433 inhibition 
predominantly protects against cardiac fibrosis in the 
remodeling phase after MI or prevents cardiac 
infarction in the acute phase after MI. Based on TTC 
staining, there was no difference in the infarct size 
between mice treated with miR-433 antagomir or 
negative control, strongly suggesting that miR-433 
inhibition predominantly protects against cardiac 
fibrosis in the remodeling phase after MI (Figure 2E). 
To further confirm the effect of miR-433 
inhibition in preventing cardiac fibrosis, we used a 
cardiotropic AAV9 delivery system to achieve cardiac 
inhibition of miR-433 in vivo. Mice received a 
single-bolus tail vein injection of either miR-433 
sponge AAV9 or miR-scramble. After 1 week, mice 
were subjected to LAD ligation and sacrificed at 3 
weeks post-MI. Using qRT-PCR, we confirmed that 
miR-433 sponge AAV9 efficiently reduced miR-433 
expression level in heart tissues (Figure 3A). 
Furthermore, our data showed that AAV9-mediated 
inhibition of miR-433 could significantly preserve left 
ventricular EF and FS (Figure 3B), and reduce 
increased systolic LVID and diastolic LVID in mice 3 
weeks post-MI (Supplemental Table 5). Cardiac 
inhibition of miR-433 also reduced collagen 
deposition and collagen content in hearts post-MI 
(Figure 3C-D). These data provide strong evidence 
that inhibition of miR-433 has cardioprotective effect 
against fibrosis. 
 
 
  
Figure 3: Cardiac inhibition of miR-433 via AAV9 attenuates cardiac fibrosis and preserves ventricular function post-myocardial infarction. A, 
decreased miR-433 in hearts from mice treated with miR-433 sponge AAV9 (n=6); B, preserved left ventricular fractional shortening (FS) and ejection fraction (EF); 
C, reduced cardiac fibrosis; D, decreased collagen content in myocardial infarction (MI) interfered with miR-433 sponge AAV9, as evidenced by echocardiography 
(n=6), Masson’s trichrome staining (n=4), and Sircol assay (n=4). Scale bar: 100 μm. *, P<0.05, **, P<0.01, ***, P<0.001 versus respective controls. 
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Figure 4: Antagonizing miR-433 attenuates cardiac fibroblasts proliferation and their differentiation into myofibroblasts in vivo. A-B, decreased 
cardiac fibroblasts proliferation; C, reduced differentiation into myofibroblasts in myocardial infarction (MI) with miR-433 inhibition, as determined by 
immunofluorescent staining for Vimentin and Ki-67 or pHH3 or α-SMA (n=4); D, decreased α-SMA, Col1a1, and Col3a1 in MI mice with miR-433 inhibition (n=4); 
E, Agilent gene arrays and KEGG pathway analysis identified extracellular matrix (ECM) receptor interaction as the most affected pathway in MI hearts with miR-433 
inhibition (n=4); F, decreased TGF-β, CTGF, Col1a1, Col3a1 and α-SMA and increased MMP2 and MMP9 after treatment with miR-433 antagomir in MI mice (n=4). 
Scale bar: 20 μm. *, P<0.05, **, P<0.01, ***, P<0.001 versus respective controls. 
 
Inhibition of miR-433 Attenuates Cardiac 
Fibroblast Proliferation and Myofibroblast 
Differentiation In Vivo and In Vitro 
The transformation of fibroblasts into 
myofibroblasts is a critical event in the genesis of 
cardiac fibrosis [28, 29]. We determined the effects of 
miR-433 inhibition on cardiac fibroblasts proliferation 
and their differentiation into myofibroblasts in both 
post-MI mice and cultured cardiac fibroblasts. Based 
on the heart samples from in vivo experiments, 
immunofluorescence analysis revealed that 
antagonizing miR-433 decreased cardiac fibroblast 
proliferation as evidenced by reduced 
Ki-67/Vimentin or phospho-HistoneH3 
(pHH3)/Vimentin double positive cells (Figure 4A-B). 
Furthermore, miR-433 inhibition also attenuated the 
differentiation of cardiac fibroblasts into 
myofibroblasts as shown by decreased number of 
cells double-positive for α-SMA and Vimentin (Figure 
4C). Consistent with this, the expression levels of 
α-SMA, Col1a1, and Col3a1 in the ventricle following 
MI were also attenuated by miR-433 inhibition (Figure 
4D). Agilent gene arrays were used to compare the 
difference of gene expressions between ventricle 
samples from miR-433 antagomir or scrambled 
negative control post-MI (Supplemental Tables 6-7). 
The KEGG pathway analysis based on dysregulated 
genes showed that extracellular matrix (ECM) 
receptor interaction was the most affected pathway 
(Figure 4E). Also, the protein levels of pro-fibrotic 
genes (TGF-β, α-SMA, CTGF, Col1a1, and Col3a1) 
were decreased, while genes responsible for collagen 
degradation (MMP2 and MMP9) were further 
increased by miR-433 inhibition in post-MI hearts 
(Figure 4F). Similar results were obtained for 
fibrosis-associated genes in miR-433 sponge 
AAV9-treated MI mice (Supplemental Figure 2). 
To gain mechanistic insight into the role of 
miR-433 in regulating fibrosis, we investigated the 
effect of miR-433 overexpression in cardiac fibroblasts 
in vitro. miR-433 overexpression promoted 
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proliferation and differentiation of cardiac fibroblasts, 
as evidenced by an increase in EdU and α-SMA 
staining and increased expression levels of α-SMA, 
Col1a1, Col3a1, CTGF, and TSP-1 (Figure 5). 
However, up-regulation of miR-433 failed to further 
enhance cardiac fibroblasts proliferation and 
differentiation in the presence of either TGF-β or Ang 
II stimulation (Figure 5). Contrary to the effects of 
miR-433 overexpression, inhibition of miR-433 
decreased cardiac fibroblasts proliferation and 
differentiation (Figure 6). Collectively, these data 
indicate that inhibition of miR-433 attenuates 
proliferation of cardiac fibroblasts and their 
differentiation into myofibroblasts both in vitro and in 
vivo. 
AZIN1 and JNK1 are Identified as Two Target 
Genes of miR-433  
AZIN1 is reported to be a target gene of miR-433 
in renal fibrosis [21]. However, its role in cardiac 
fibroblasts is not known. We first performed 
luciferase reporter assays to confirm that miR-433 
could directly target the 3’UTR of AZIN1 in both 293T 
cells and cardiac fibroblasts (Figure 7A). Next, we 
investigated whether AZIN1 could potentially 
mediate the effects of miR-433 in cardiac fibrosis. In 
cardiac fibroblasts, the expression level of AZIN1 was 
decreased by miR-433 agomir but increased by 
miR-433 antagomir as determined by Western 
blotting (Figure 7B-C), indicating that miR-433 could 
regulate endogenous AZIN1 expression levels. We 
next used AZIN1 overexpression plasmid to 
determine AZIN1’s role in mediating the effect of 
miR-433 on cardiac fibroblasts proliferation and 
differentiation into myofibroblasts. Our data 
illustrated that overexpression of AZIN1 could 
attenuate the pro-fibrotic effect of miR-433 agomir on 
cardiac fibroblasts (Figure. 7D-F). Also, AZIN1 
knockdown via siRNA failed to have an additive 
effect on fibroblast proliferation and myofibroblast 
differentiation in cells co-treated with miR-433 agomir 
(Supplemental Figure 3). These data strongly suggest 
that AZIN1 is a target gene of miR-433 mediating its 
effect in cardiac fibrosis. 
 
 
Figure 5: miR-433 promotes cardiac fibroblasts proliferation and their differentiation into myofibroblasts in vitro.A, increased miR-433 in cardiac 
fibroblasts treated with miR-433 agomir (n=6); B, enhanced cardiac fibroblasts proliferation and their differentiation into myofibroblasts (n=4); C-D, upregulated 
fibrosis-related genes in cardiac fibroblasts with miR-433 overexpression in the absence of TGF-β stimulation, as evidenced by EdU/α-SMA staining (n=4), qRT-PCR 
(n=6), and Western blot analysis (n=4); E-F, upregulated fibrosis-related genes in cardiac fibroblasts with miR-433 overexpression in the absence of Angiotensin II 
stimulation. Scale bar: 50 μm. *, P<0.05, **, P<0.01, ***, P<0.001 versus respective controls.  
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Figure 6: Inhibition of miR-433 attenuates TGF-β/Ang II-induced cardiac fibroblasts proliferation and their differentiation into myofibroblasts in vitro. A, decreased 
miR-433 in cardiac fibroblasts treated with miR-433 antagomir (n=6); B, reduced cardiac fibroblasts proliferation and their differentiation into myofibroblasts (n=4); 
C-D, downregulated fibrosis-related genes in cardiac fibroblasts with miR-433 inhibition regardless of TGF-β stimulation, as evidenced by EdU/α-SMA staining (n=4), 
qRT-PCR (n=6), and Western blot analysis (n=4); E-F, downregulated fibrosis-related genes in cardiac fibroblasts with miR-433 inhibition regardless of Angiotensin 
II stimulation. Scale bar: 50 μm. *, P<0.05, **, P<0.01, ***, P<0.001 versus respective controls. 
 
As AZIN1 was previously reported to be linked 
to TGF-β signaling in both kidney and liver fibrosis 
[21, 22], we further examined the modulatory effect of 
AZIN1 on TGF-β and its downstream effector Smad3. 
Our data revealed that knockdown of AZIN1 could 
upregulate TGF-β expression and activate Smad3 
phosphorylation, while overexpressing AZIN1 had an 
opposite effect (Figure 8), indicating a potential 
relationship between AZIN1 and TGF-β/Smad3 
signaling in the regulation of cardiac fibrosis. 
Besides AZIN1, bioinformatic analysis using 
Targetscan indicated that JNK1 might be an 
additional potential target gene of miR-433 (Figure 
9A). Luciferase reporter assays further confirmed that 
miR-433 led to a reduction in luciferase activity for the 
wild-type 3’UTR construct for JNK1, but had no effect 
when the miR-433 binding site in the JNK1 3’UTR was 
mutated, implying that JNK1 is a direct target of 
miR-433 (Figure 9A). To check if miR-433 could 
regulate endogenous JNK1 expression in cardiac 
fibroblasts, miR-433 agomir, antagomir, or their 
negative controls were transfected into cardiac 
fibroblasts. As determined by Western blotting, 
miR-433 agomir decreased, while miR-433 antagomir 
increased JNK1 expression (Figure 9B-C), confirming 
that miR-433 could regulate endogenous JNK1 
expression levels in cardiac fibroblasts. In addition, 
we used JNK1 overexpression plasmid to determine 
its role in the miR-433-mediated cardiac fibroblasts 
proliferation and differentiation into myofibroblasts. 
Our results clearly indicated that overexpression of 
JNK1 could attenuate the pro-fibrotic effect of 
miR-433 agomir on cardiac fibroblasts (Figure 9D-F). 
JNK1 knockdown via siRNA, on the other hand, did 
not further increase fibroblast proliferation, though 
myofibroblast differentiation was slightly enhanced in 
cells co-treated with miR-433 agomir (Supplemental 
Figure 4). These data identify JNK1 as a novel target 
gene of miR-433 contributing to cardiac fibroblast 
proliferation and myofibroblast differentiation. 
As a member of mitogen-activated protein 
kinase (MAPK) family, JNK1 may have functional 
cross-talk with two other members of MAPK family, 
namely ERK and p38 kinase [30, 31]. To confirm this, 
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JNK1 was knocked down by siRNA and the 
expression levels of ERK and p38 kinase were 
determined by Western blotting. We observed that 
JNK1 knockdown significantly activated ERK and p38 
kinase as evidenced by increased ratios of 
p-ERK/ERK and p-p38/p38, paralleling with the 
activation of Smad3 (Figure 10A). However, the 
introduction of the JNK1 overexpression plasmid 
resulted in reduced phosphorylation levels of 
ERK1/2, p38, and Smad3 (Figure 10B). Interestingly, 
inhibition of p38, ERK or Smad3 could block the 
positive effects of miR-433 agomir on cardiac 
fibroblasts proliferation and differentiation, as 
determined by α-SMA and EdU staining, and reduce 
the expression levels of α-SMA, Col1a1, and Col3a1 
(Figure 10 C-D).  
To examine whether AZIN1 and JNK1 could be 
regulated during cardiac fibrosis and/or miR-433 
inhibition, we first examined their expression levels in 
vivo in the heart samples from post-MI rodent model, 
doxorubicin-induced cardiomyopathy rodent model, 
and human dilated cardiomyopathy. Consistently, 
both AZIN1 and JNK1 were down-regulated in these 
three fibrotic conditions at both protein and mRNA 
levels (Figure 11A-B). We next tested whether AZIN1 
and JNK1 were increased in ventricle samples of 
miR-433 antagomir-injected mice. As determined by 
gene arrays, we did not detect changes of AZIN1 and 
JNK1 at the mRNA level. However, considering the 
fact that miRNAs regulate their target genes mostly at 
posttranscriptional levels, we also determined AZIN1 
and JNK1 protein levels by Western blotting. Our 
results clearly showed that treatment with miR-433 
antagomir increased the expression of AZIN1 and 
JNK1 in the presence or absence of MI (Figure 11C). 
These data are consistent with the hypothesis that one 
or both genes are target genes of miR-433 in vivo. 
Interestingly, during MI, miR-433 antagomir 
inactivated ERK and p38 kinase as evidenced by the 
decreased ratio of p-ERK/ERK and p-p38/p38, 
together with Smad3 (Figure 11C).  
 
 
 
 
Figure 7: AZIN1 is a target gene of miR-433 in cardiac fibroblasts. A, Targetscan and Luciferase reporter assays identified AZIN1 as a direct target gene of 
miR-433 (n=6); B-C, AZIN1 was negatively regulated by miR-433 in cardiac fibroblasts (n=3); D-F, Overexpression of AZIN1 via pEGFP plasmid attenuated the 
pro-fibrotic effect of miR-433 agomir on cardiac fibroblasts proliferation and their differentiation into myofibroblasts. n=3 for Western blot, n=4 for EdU and α-SMA 
staining, n=6 for qRT-PCR. Scale bar: 50 μm. *, P<0.05, **, P<0.01, ***, P<0.001 versus respective controls. 
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Figure 8: AZIN1 inactivates TGF-β/Smad3 signaling in cardiac fibroblasts. A, Knockdown of AZIN1 could upregulate TGF-β expression and activate 
Smad3 phosphorylation (n=3); B, Overexpression of AZIN1 had opposite effects (n=3). *, P<0.05, **, P<0.01, ***, P<0.001 versus respective control. 
 
 
Figure 9: JNK1 is a novel target gene of miR-433 in cardiac fibroblasts. A, Targetscan and Luciferase reporter assays identified JNK1 as a direct target gene 
of miR-433 (n=6); B-C, JNK1 was negatively regulated by miR-433 in cardiac fibroblasts (n=3); D-F, Overexpression of JNK1 via pEGFP plasmid attenuated the 
pro-fibrotic effect of miR-433 agomir on cardiac fibroblasts proliferation and their differentiation into myofibroblasts. n=3 for Western blot, n=4 for EdU and α-SMA 
staining, n=6 for qRT-PCR. Scale bar: 50 μm. *, P<0.05, **, P<0.01, ***, P<0.001 versus respective controls. 
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Figure 10: JNK1 knockdown significantly activates ERK and p38 kinase. A, JNK1 knockdown via siRNA increased ERK, p38, and Smad3 phosphorylation 
(n=3); B, Overexpression of JNK1 via pEGFP plasmid had opposite effects (n=3); C-D, reduced cardiac fibroblasts proliferation and their differentiation into 
myofibroblasts in cells treated with miR-433 agomir and inhibitor of p38, ERK, or Smad3. n=4 for EdU and α-SMA staining, n=6 for qRT-PCR. Scale bar: 50 μm. *, 
P<0.05, **, P<0.01, ***, P<0.001 versus respective controls.  
 
Discussion 
Myocardial fibrosis is a common hallmark in a 
variety of cardiomyopathies [4]. Consequently, 
anti-fibrotic therapies are increasingly considered as 
an extremely promising approach for the treatment of 
heart failure [3]. Unfortunately, effective strategies to 
attenuate cardiac fibrosis are not available [2]. 
Aberrant expression of various miRNAs has been 
shown to play a crucial role in cardiac fibrosis and 
heart failure [1, 32]. These small non-coding miRNAs 
with conserved sequences have become promising 
therapeutic candidates from a drug development 
standpoint [7]. Recently, manipulating miRNAs for 
developing anti-fibrotic therapies has emerged as a 
novel treatment strategy for fibrotic changes [1, 33].  
According to the miRBase 21 release, 1881 
miRNAs have been identified in humans. Numerous 
studies have demonstrated the involvement of many 
of these miRNAs in vital cellular processes. However, 
the role of miRNAs in the heart and especially for 
cardiac fibrosis is unclear. It has been suggested that 
dysregulated miRNAs such as miR-21 and miR-29b, 
contribute to cardiac fibrosis [16, 18]. Using miRNA 
arrays, we identified elevated levels of miR-433 in 
post-MI cardiac fibrosis. The same modulation was 
also observed in other cardiac pathologies, including 
doxorubicin-induced cardiomyopathy in a rodent 
model, and in a limited number of human DCM 
samples, indicating that upregulation of miR-433 
might be a common feature of adverse cardiac 
remodeling. Besides cardiac pathologies, miR-433 has 
been reported to be downregulated in human gastric 
carcinoma. Ectopic expression of miR-433 in the 
gastric cancer cell line HGC-27 could inhibit cellular 
proliferation, migration, invasion, and cell cycle 
progression [34]. miR-433 also inhibits liver cancer cell 
migration and oral squamous cell carcinoma (OSCC) 
cell growth and metastasis [35, 36], indicating that 
miR-433 acts as a tumor suppressor. In other studies, 
miR-433 has been shown to promote renal fibrosis and 
also TGF-β-dependent fibrogenesis in liver and 
kidney [21, 22]. In another report, miR-433 has been 
described to promote resistance to paclitaxel through 
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the induction of cellular senescence in ovarian cancer 
cells [37]. These data point to the complex tissue- and 
cell-based specific roles of miR-433 in various cancers. 
The role of miR-433 in the heart and during 
cardiac fibrosis had not been investigated previously. 
The proliferation and transformation of cardiac 
fibroblasts into myofibroblasts are key events for 
cardiac fibrosis [29]. Fibroblast proliferation and 
myofibroblast differentiation can be differentially 
regulated by growth factors such as TGF-β , EGF, 
PDGF, CTGF, and IGF [38]. Herein, we demonstrated 
that miR-433 over-expression enhanced both cardiac 
fibroblast proliferation and their differentiation into 
myofibroblasts, whereas inhibition of miR-433 
attenuated these processes, indicating the critical 
stimulatory effect of miR-433 on cardiac fibroblast 
activation. We also observed that miR-433 was 
enriched in cardiac fibroblasts compared to 
cardiomyocytes. Furthermore, overexpression of 
miR-433 in cardiomyocytes does not appear to play a 
role in cardiomyocyte biology, as seen by the lack of 
effect on markers for pathological hypertrophy and 
extracellular matrix proteins.  
A previously reported target gene of miR-433 in 
renal fibrosis, AZIN1, has been linked to TGF-β 
signaling in both kidney and liver fibrosis [21, 22]. It is 
an ornithine decarboxylase (ODC) homolog that binds 
to antizyme with a higher affinity [21, 22]. 
Suppression of AZIN1 expression results in antizyme 
repression followed by a decline of polyamine levels 
and consequent activation of the TGF-β signaling 
pathway to promote fibrosis [21, 22]. To date, very 
little information is available on the role of AZIN1 in 
cardiac pathologies. In this study, AZIN1 appeared to 
be responsible for the effects of miR-433 in cardiac 
fibroblasts. It was downregulated in the heart tissues 
from post-MI mice, doxorubicin-induced 
cardiomyopathy rodent model, and human dilated 
cardiomyopathy, indicating its potential role in the 
diseased myocardium with fibrosis. Furthermore, 
knockdown of AZIN1 could promote proliferation 
and differentiation of cardiac fibroblasts into 
myofibroblasts accompanied with an activation of 
TGF-β/Smad3 signaling pathway. However, the 
direct relationship between AZIN1 and TGF-β1 and 
their functional roles in the regulation of cardiac 
fibrosis needs to be further clarified through the 
function-rescue assay. Taken together, these results 
suggest that AZIN1 is a target gene of miR-433 in 
cardiac fibrosis and also provide evidence for the 
functional role of AZIN1 in the heart that needs to be 
explored in the future. 
 
 
Figure 11: AZIN1 and JNK1 are downregulated by miR-433 antagomir in vivo. A-B, downregulated AZIN1 and JNK1 in ventricular samples from 21 day 
post-myocardial infarction (MI) mice, rodent model of doxorubicin (Dox)-induced cardiomyopathy, and human dilated cardiomyopathy (DCM). For Western blot, 
n=3. For qRT-PCR, n=3 for mice and n=4 for patients; C, Upregulated AZIN1 and JNK1, accompanied by an inactivation of ERK, p38, and Smad3 phosphorylation in 
MI hearts with miR-433 inhibition (n=4). *, P<0.05, **, P<0.01, ***, P<0.001 versus respective controls. 
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Besides AZIN1, based on bioinformatic analysis 
and experimental validation, JNK1 was identified as a 
novel target gene of miR-433 in cardiac fibroblasts. 
Jun NH2-terminal kinases, including three isoforms 
(JNK1, JNK2, and JNK3), belong to the MAPK family 
and play major roles in development, cell 
proliferation, differentiation, and apoptosis [31, 39]. 
JNK1 and JNK2 are abundant in myocardium while 
JNK3 is most abundant in the brain [31, 39]. In this 
study, luciferase assays demonstrated that JNK1 was 
a direct target of miR-433 and Western blot analysis 
confirmed that miR-433 could endogenously regulate 
JNK1 expression in cardiac fibroblasts. Functional 
studies in cardiac fibroblasts further indicated that 
reduction of JNK1 was responsible for the pro-fibrotic 
effects of miR-433 in cardiac fibroblasts. Furthermore, 
JNK1 may also have a functional cross-talk with ERK 
and p38 kinase, two other members of MAPK family 
[30]. ERK and p38 kinase pathways were activated 
while JNK1 was inhibited in the heart samples from 
post-MI mice, doxorubicin-induced cardiomyopathy 
rodent model, and human dilated cardiomyopathy. 
Also, reduction of JNK1 in cardiac fibroblasts 
activated ERK and p38 kinase and inhibition of ERK 
and p38 kinase attenuated the biological effects of 
miR-433 agomir on the proliferation and 
differentiation of cardiac fibroblasts. Collectively, 
these results suggest that miR-433 downregulates 
JNK1 and subsequently activates ERK and p38 kinase 
promoting cardiac fibrosis. 
The protective effects of miR-433 inhibition 
against cardiac fibrosis were confirmed by 
antagonizing miR-433 or inhibiting miR-433 via 
cardiotropic AAV9, which attenuated cardiac fibrosis 
and preserved ventricular function post-MI. Although 
several lines of evidence presented here strongly 
supports the functional role of miR-433 in regulating 
cardiac fibrosis, more rigorous approaches are 
required to support this contention. These may 
include intra-myocardial rather than systemic 
delivery with a cardiac fibroblast-specific promoter 
and/or using a miR-433 transgenic mouse model 
created by using the cardiac fibroblast-specific 
promoter. 
It is of note that cardiac fibrosis was decreased 
with the miR-433 antagomir but not abolished 
indicating the involvement of other pathways. For 
example, some clustered miRNAs of miR-433 
including miR-431, miR-434 and miR-127 were also 
elevated in our initial miRNA array based on fibrotic 
heart samples post-MI. These miRNAs might work 
coordinately to promote cardiac fibrosis. It would also 
be interesting to further determine in vivo therapeutic 
roles for each of miR-433 targets, alone or in 
combination, by gain-of-function and loss-of-function 
studies. Furthermore, the therapeutic effects of 
miR-433 reduction on cardiac fibrosis in an 
established model need to be determined in the 
future. Last but not least, as cardiac fibrosis in the 
acute phase post-MI may protect the ischemic heart 
from structural rupture [40], the effect as well as the 
safety of miR-433 inhibition in the treatment of 
cardiac fibrosis must be carefully evaluated during 
the early phase post-MI. Notably, the data from the 
present study demonstrated that antagonizing 
miR-433 in vivo did not impact the infarct size 3 days 
after MI surgery suggesting that inhibition of miR-433 
does not affect infarct size during the early phase 
post-MI. 
 In summary, our study has shown that miR-433 
is induced by cardiac fibrosis, subsequently reducing 
the expression of AZIN1 and JNK1. Decreased AZIN1 
activates TGF-β1 pathway while down-regulated 
JNK1 leads to activation of ERK and p38 kinase 
stimulating Smad3 and ultimately leading to cardiac 
fibrosis 
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